Latest Northwest Biotherapeutics Stories
Endpoint of Tumor Regression Could Be Seen Within Months BETHESDA, Md., March 5, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, announced today that its Phase I/II DCVax-Direct clinical trial for all inoperable solid tumor cancers is planned to begin within approximately the next sixty days. As a Phase I/II trial, this trial is not blinded and the results...
BETHESDA, Md., Feb. 15, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that, building upon nearly three years of manufacturing development, regulatory processes and clinical preparations in Europe, the Company has named a leading international contract research organization (CRO) to manage the Company's 312-patient Phase III clinical trial for...
BETHESDA, MD, Feb. 11, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Linda F. Powers, the Company's Chairman and Chief Executive Officer, will be presenting at the 15(th) Annual BIO CEO and Investor Conference at 4:30 p.m. on Monday, February 11, 2013 at the Waldorf Astoria Hotel in New York City. (Logo:...
BETHESDA, Md., Jan. 29, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for cancer, announced today that Dr. Marnix Bosch, the Company's Chief Technical Officer, will be presenting at the Phacilitate Cell And Gene Therapy Forum 2013, today at 3:30 pm in a session entitled Clinical Development Updates: Oncology. The conference is being held at the Grand Hyatt Hotel at 10(th) and H...
BETHESDA, Md., Dec. 17, 2012 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO; NWBOW) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that it is scheduled to ring The NASDAQ Stock Market Opening Bell on Tuesday, December 18, 2012 to celebrate the Company's recent financing and up-listing to the NASDAQ Capital Market. NW Bio's common stock and warrants began trading on NASDAQ on December 7, 2012. (Logo:...
BETHESDA, Md., Sept. 26, 2012 /PRNewswire/ -- Northwest Biotherapeutics (NWBO:OTC QB) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced that on September 25, 2012 at 5:00 p.m. EDT (the "Effective Date") it effected a one (1) for sixteen (16) reverse split of its issued and outstanding common stock (the "Reverse Split") as a first step in a planned public offering of up to $25 million and listing of its common stock on the...
BETHESDA, Md., Sept. 20, 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that it is in late stage discussions with medical centers in the U.S. and Europe to proceed with a Phase I/II clinical trial with the Company's third major product line, DCVax(®)-Direct, for all types of solid tumor cancers (i.e., cancers in any tissues). The Company previously received...
BETHESDA, Md., Sept. 18, 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that it has appointed former pharmaceutical industry executive Dr. Gunter Rosskamp as the CEO of the Company's German subsidiary, Northwest Biotherapeutics, Gmbh. (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO) Dr. Rosskamp brings extensive experience as a senior...
BETHESDA, Md., Aug. 23, 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) announced today that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom (the U.K.'s "FDA"), for the Company's 300-patient Phase III clinical trial of DCVax(®)-L immune therapy for Glioblastoma multiforme brain cancer (GBM) to proceed in the U.K. (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO) This Phase...
BETHESDA, Md., Aug. 8, 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio or the Company) announced today that it is entering into amended agreements to double the production capacity in the U.S. for the manufacture of the Company's DCVax(®)-L immune therapy for Glioblastoma multiforme (GBM) patients. Manufacturing is also commencing in Europe, with production already fully operational in Germany, and in the final stages of preparation in the U.K. These...
